CYP26A1 Inhibitors
CYP26A1 inhibitors belong to a specific category of chemical compounds that modulate the function of cytochrome P450 family 26 subfamily A member 1 (CYP26A1) enzyme. CYP26A1 is a crucial player in the intricate metabolism of retinoic acid, a derivative of vitamin A. It achieves this through catalyzing the degradation of retinoic acid. The pursuit of inhibiting CYP26A1 centers on the aim of altering the enzymatic activity, which can lead to the accumulation of retinoic acid, an influential molecule involved in various cellular and developmental processes. The structural diversity of CYP26A1 inhibitors encompasses a range of chemical frameworks, each engineered with specific functional groups that enable precise binding to key sites within the enzyme's structure. These interactions hold the ability to disrupt the catalytic function of CYP26A1 and influence the complex network of retinoic acid metabolism. As ongoing research delves deeper into the intricacies of CYP26A1 inhibition, novel insights continue to emerge, unveiling avenues for the modulation of retinoic acid-related pathways.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Liarozole hydrochloride | 145858-50-0 | sc-204055 sc-204055A | 10 mg 50 mg | $159.00 $500.00 | 1 | |
"Liarozole hydrochloride (CAS 145858-50-0) is a chemical compound known for inhibiting CYP26A1, a key enzyme in retinoic acid metabolism. | ||||||
N,N′-Octamethylenebis(2,2-dichloroacetamide) | 1477-57-2 | sc-295819 sc-295819A | 250 mg 1 g | $180.00 $374.00 | 7 | |
WIN 18,446 is a synthetic compound that has been studied for its potential to inhibit CYP26 enzymes, including CYP26A1, and thereby increase retinoic acid levels. | ||||||
4-Hydroxyphenylretinamide | 65646-68-6 | sc-200900 sc-200900A | 5 mg 25 mg | $104.00 $315.00 | ||
Fenretinide has been shown to inhibit CYP26A1 and contribute to increased retinoic acid levels. | ||||||
4-Formyl-N-phenyl-benzamide | 179057-23-9 | sc-336439 | 1 g | $500.00 | ||
Certain benzamide derivatives have been identified as potential inhibitors of CYP26A1, with implications for retinoic acid signaling. | ||||||
Flufenamic acid | 530-78-9 | sc-205699 sc-205699A sc-205699B sc-205699C | 10 g 50 g 100 g 250 g | $27.00 $79.00 $154.00 $309.00 | 1 | |
Fenamate compounds have been investigated for their potential to inhibit CYP26A1 and modulate retinoic acid metabolism. | ||||||
13-cis-Retinoic acid | 4759-48-2 | sc-205568 sc-205568A | 100 mg 250 mg | $75.00 $120.00 | 8 | |
Isotretinoin has been studied for its effects on retinoic acid metabolism through inhibition of CYP26A1. | ||||||
Ginsenoside Rg3 | 14197-60-5 | sc-204767 sc-204767A | 5 mg 10 mg | $202.00 $340.00 | 1 | |
Certain ginsenosides have been studied for their potential to inhibit CYP26A1 and modulate retinoic acid metabolism. | ||||||
Topotecan Hydrochloride | 119413-54-6 | sc-204919 sc-204919A | 1 mg 5 mg | $45.00 $102.00 | 2 | |
Topotecan has been explored for its inhibitory effects on CYP26A1 and retinoic acid metabolism. | ||||||